Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nutripharmaceuticals for osteoarthritis.

H J Häuselmann1

  • 1Centre for Rheumatology and Bone Disease, Klinik Im Park, Bellariastr.38, CH 8038, Switzerland.

Best Practice & Research. Clinical Rheumatology
|September 25, 2001
PubMed
Summary

Current symptomatic agents (SYSADOA) like chondroitin and glucosamine show limited evidence for osteoarthritis pain relief, especially in high-quality studies. Reliable scientific evidence for structure-modifying effects or benefits in hip or hand osteoarthritis is lacking.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis: report of a task force of ESCISIT.

Annals of the rheumatic diseases·2008
Same author

[Implantation of matrix-free cartilage transplants in standardized defects in sheep knee joints].

Der Orthopade·2006
Same author

EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Annals of the rheumatic diseases·2006
Same author

Generation of a scaffold free cartilage-like implant from a small amount of starting material.

Journal of cellular and molecular medicine·2006
Same author

Level of acceptability of EULAR recommendations for the management of knee osteoarthritis by practitioners in different European countries.

Annals of the rheumatic diseases·2005
Same author

EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Annals of the rheumatic diseases·2004

Area of Science:

  • Rheumatology
  • Pharmacology
  • Evidence-Based Medicine

Background:

  • Osteoarthritis (OA) is a degenerative joint disease causing pain and functional decline.
  • Symptomatic slow-acting drugs for osteoarthritis (SYSADOA) are widely used for OA management.
  • The scientific evidence supporting the efficacy and structure-modifying potential of SYSADOA remains a subject of ongoing research and debate.

Purpose of the Study:

  • To evaluate the level of scientific evidence for SYSADOA in patients with osteoarthritis.
  • To assess the efficacy of chondroitin sulphate and glucosamine sulphate on pain, function, and cartilage in OA.
  • To determine if SYSADOA possess structure-modifying properties.

Main Methods:

  • Systematic review and meta-analysis of existing publications meeting inclusion criteria.

Related Experiment Videos

  • Calculation of effect sizes for primary outcomes (pain, function, WOMAC index).
  • Quality assessment of study methodologies to evaluate reliability of findings.

    • Main Results:

    • Median effect size for pain was 1.37 for chondroitin sulphate and 0.57 for glucosamine sulphate in knee OA.
    • Effect sizes for pain were significantly diminished in recent high-quality studies (0.37 for chondroitin, 0.26 for glucosamine).
    • No reliable scientific evidence supports structure-modifying actions (cartilage healing/restoration) for these agents; evidence for hip/hand OA is scarce.

    Conclusions:

    • Current symptomatic agents (SYSADOA) demonstrate limited efficacy for osteoarthritis pain relief, particularly when considering high-quality recent research.
    • There is a lack of robust scientific evidence to support the claimed structure-modifying effects of chondroitin and glucosamine in osteoarthritis.
    • Further large-scale trials are underway to clarify the role of these nutripharmaceuticals in osteoarthritis management.